3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term loan credit from the International Finance Corporation (IFC), with the funds designated for the construction of manufacturing facilities and the development of overseas business.
This development signifies that 3SBio, the first Chinese biopharmaceutical enterprise to partner with the IFC, has garnered comprehensive recognition from the international capital market regarding its business strategy, corporate governance, and future growth potential. It underscores the company’s overall strength in various aspects.
The IFC, an international financial institution, provides investment, advisory, and asset management services aimed at fostering private-sector development in less developed countries. As a member of the World Bank Group, the IFC is headquartered in Washington, D.C., in the United States.- Flcube.com
